P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1061-1067

  Baekelandt, Mark M ^a   Holm, Ruth ^a   Nesland, Jahn M ^a   Tropé, Claes G ^a   Kristensen, Gunnar B ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Multidrug resistance; Ovarian cancer; P glycoprotein; Prognosis

Indexed keywords

CISPLATIN; EPIRUBICIN; GLYCOPROTEIN P;

ADULT; ADVANCED CANCER; AGE; ARTICLE; ASCITES; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LAPAROTOMY; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; TUMOR VOLUME;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034053339     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
2. Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 455: 152-162, 1976.
3. Bradshaw DM and Arceci RJ: Clinical relevance oftransmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16: 3674-3690, 1998.
4. Hamada H and Tsuruo T: Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Nat Acad Sci USA 83: 7785-7789, 1986.
5. Nooter K and Sonneveld P: Clinical relevance of P-glycoprotein in haematologieal malignancies. Leucemia Res 18: 233-243, 1994.
6. Chan H, Haddad G, Thorner P, De Boer G, Lin YP, Ondrusek N, Yeger H and Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. New Engl J Med 325: 1608-1614, 1991.
7. Chan H, Thorner PS, Haddad G and Ling V: Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft-tissue sarcoma of childhood. J Clin Oncol 8: 689-704, 1990.
8. Kristensen GB and Trope CG: Epithelial ovarian cancer. Lancet 349: 113-117, 1997.
9. Cordon-Cardo C, O'Brien JP, Boccia J, Casals P, Bertino JR and Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287, 1990.
10. Rubin SC, Finstad CL, Hoskins WJ, Saigo PE, Provencher DM, Federici MG, Hakes TB, Markman M, Reichman BS, Lloyd KO and Lewis JL: Expression of P-glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 163: 69-73, 1990.
11. van der Zee AG, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PH, Zijlstra JG and de Vries ECE: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915-5920, 1991.
12. Schneider J, Efferth T, Kaufmann M, Matia JC and Mattern J: Expression of the multidrug-resistance gene product P-glycoprotein in gynecological tumors. Cancer J 3: 202-205, 1990.
13. Rutledge ML, Robey-Cafferty SS, Silva EG and Bruner JM: Monoclonal antibody C219 detection of the multidrug-resistant protein P-glycoprotein in routinely processed tissues: A study of 36 cases of ovarian carcinoma. Modern Pathol 3: 298-301, 1990.
14. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H and Fukumoto M: Expression of multidrug resistance gene and localization of P-glyconrotein in human primary ovarian canter. Cancer Res 54: 1355-1359, 1994.
15. Mcgown AT, Murphy D, Swindell R, Crowther D and Fox BW: Correlation of drug resistance-associated parameters in ovarian tumor biopsies. Int J Gynceol Cancer 4: 241-249, 1994.
16. van der Zee AG, Hollema HH, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG and de Vries EGE: Value of P-glycoprotein, glutathione S-transferase pi, c- erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70-78, 1995.
17. Kavallaris M, Leary JA, Barrett JA and Friedlander ML: MDR1 associated prolein (MRP) gene expression in epithelial ovarian tumors. Cancer Letters 102: 7-16, 1996.
18. International Federation of Gynecology and Obstetrics: Annual report on the results of treatment in gynecologic cancer. Int J Gynecol Obstet 28: 189-190, 1989.
19. Serov SF, Scully RE and Sobin LH: Histological typing of ovarian tumors. In: World Health Organization: International histological classification oftumors. Geneva, WHO, 1973, vol 9, pp 37-42.
20. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
21. Scheper RJ, Bulte JW, Brakkee JG, Quak JJ, van der Sloot E and Balm AJ: Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int J Cancer 42: 389-394, 1988.
22. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
23. Cox DR: Regression models and life tables. J R Stat Soc Ser B 34: 187-220, 1972.
24. Baekelandt M, Kristensen GB, Nesland JM, Tropé CG and Holm R: Clinical significance of apoptosis-related factors p53, Mdm2 and Bcl-2 in advanced ovarian cancer. J Clin Oncol 17: 2061-2068, 1999.
25. Bell DR, Gerlach JH, Kartner N, Buick RN and Ling V: Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance. J Clin Oncol 3: 311-315, 1985.
26. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM and Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269, 1987.
27. Beck WT, Grogan TM, Willman CL, Willman CL, Cordon-Cardo C, Parham D, et al: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recom-mendations. Cancer Res 56: 3010-3020, 1996.
28. Finstad CL, Yin BW, Gordon CM, Federici MG, Welt S and Lloyd KK: Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: A problem of quality control for immunohistochemical analysis. J Histochem Cytochem 39: 1603-1610, 1991.
29. Toth K, Vaughan MM, Slocum HK, Arredondo MA, Takita H, Baker RM and Rustum YM: New immunohistochemical "sandwich" staining method for mdrl P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am J Pathol 144: 227-236, 1994.
30. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R and Silvestrini R: Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 30A: 1002-1007, 1994.
31. Holzmayer TA, Hilsenbeck S, Von Hoff DD and Roninson I: Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84: 1486-1491, 1992.
32. Herzog CE, Trepe JB, Mickley LA, Bates SE and Fojo AT: Various methods of analysis of mdr-l/P-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst 84: 711-716, 1992.
33. Smeets M, Raymakers R, Vierwinden G, Pennings A, van de Locht L, Wessels H, Boezeman J and de Witte T: A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br J Haematol 96: 346-355, 1997.
34. Ro J, Sahin A, Ro J, Fritsche H, Hortobagyi G and Blick M: Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21: 787-791, 1990.
35. Chin K-V, Ueda K, Pastan I and Gottesman MM: Modulation of activity of the promoter ofthe human MDR1 gene by Ras and p53. Science 255: 459-462, 1992.
36. De Angelis P, Stokke T, Smedshammer L, Lothe RA, Lehne G, Chen Y and Clausen OPF: P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J cancer 72: 307-311, 1995.
37. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan T, Saclarides TJ, Roninson I and Coon JS: Relationship ofthe expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726, 1991.
38. Bradley G and Ling V: P-glycoprotein, multidrug resistance and tumor progression. Cancer Metast Rev 13: 223-233, 1994.
39. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Habert I, Andreerf M and Huber H: Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), 1L-4, and interferon-γ in normal human T lymphocytes. Blood 5: 1747-1754, 1996.
40. Bjørnland K, Lehne G, Thidemann Johansen H, Fodstadø, Rugstad HE, Aasen AO and Hansen Ree A: Human hepatoma cells rich in P-glycoprotein display enhanced in vitro invasive properties compared to P-glycoprotein-poor hepatoma cells. Oncol Res 10: 255-262, 1998.
41. Lehne G, Elonen E, Baekelandt M, Skovsgaard T and Peterson C: Challenging drug resistance in cancer therapy. Acta Oncol 37: 431-439, 1998.
42. Fisher GA and Sikic BI: Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9: 363-382, 1995.